The Diabetic and Idiopathic Gastroparesis Efficacy, Safety, and Tolerability (DIGEST) Study

Key facts

Sponsor

Theravance Biopharma

Principal Investigator

Deanna Nguyen, MD

Theravance Biopharma

Intervention

Velusetrag(drug)

Enrollment

233 target

Eligibility

18-75 years · All sexes

Timeline

2014 – 2017

Collaborators

Alfasigma S.p.A.

Primary source

Recruitment status, site addresses, contacts, and full eligibility criteria can change between syncs. Always verify with the trial team before planning travel or treatment.

Other trials for Idiopathic gastroparesis

Additional recruiting or active studies for the same condition.

• RECRUITINGNCT04661215
  Pyloric Sphincter Abnormalities in Patients With Gastroparesis Symptoms
  Johns Hopkins Bloomberg School of Public Health
• ACTIVE NOT RECRUITINGPHASE2NCT06899217
  A Study to Evaluate the Efficacy and Safety of CIN-102 (Deudomperidone) in Adult Subjects With Idiopathic Gastroparesis.
  CinDome Pharma, Inc.
• RECRUITINGNCT05981300
  GpCRC Pediatric Gastroparesis Registry 2
  Johns Hopkins Bloomberg School of Public Health
• ENROLLING BY INVITATIONNCT06581120
  GLP_1 RA Ultrasound Study
  Children's Hospital Medical Center, Cincinnati
• RECRUITINGPHASE3NCT06836557
  Open Label Safety Study of Tradipitant in Idiopathic and Diabetic Gastroparesis
  Vanda Pharmaceuticals
• RECRUITINGPHASE2NCT05621811
  Different Doses of Naronapride Vs. Placebo in Gastroparesis
  Dr. Falk Pharma GmbH
• ENROLLING BY INVITATIONNCT05812339
  Body Surface Gastric Mapping to Evaluate Patients With Upper Gastrointestinal Symptoms and Controls
  University of Calgary
• ACTIVE NOT RECRUITINGNCT03626350
  Prospective Evaluation of the Efficacy and Safety of Submucosal Endoscopy
  University of Colorado, Denver

See all trials for Idiopathic gastroparesis →